所有图片(2)
About This Item
经验公式（希尔记法）:
C20H21ClO4
CAS号:
分子量:
360.83
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
analytical standard
品質等級
化驗
≥99.0% (HPLC)
儲存期限
limited shelf life, expiry date on the label
技術
HPLC: suitable
gas chromatography (GC): suitable
雜質
≤0.3% water
應用
forensics and toxicology
pharmaceutical (small molecule)
格式
neat
SMILES 字串
CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2
InChI
1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
InChI 密鑰
YMTINGFKWWXKFG-UHFFFAOYSA-N
基因資訊
human ... PPARA(5465)
正在寻找类似产品? 访问 产品对比指南
應用
有关合适的仪器技术的更多信息，请参阅产品的分析证书。想要获得更多支持，请联系技术服务部。
訊號詞
Warning
危險聲明
危險分類
STOT RE 2 Oral
標靶器官
Liver
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Pitchai Balakumar et al.
Pharmacological research, 63(1), 8-12 (2010-11-26)
Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced
Itoro E Elijah et al.
Burns : journal of the International Society for Burn Injuries, 38(4), 481-486 (2012-01-10)
Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric
Pascale Massin et al.
Ophthalmic epidemiology, 21(5), 307-317 (2014-08-19)
Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not
Kate McKeage et al.
Drugs, 71(14), 1917-1946 (2011-09-29)
Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-α. Fenofibrate
Samuel Rommelaere et al.
PloS one, 9(8), e104925-e104925 (2014-08-21)
Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门